دنبال کردن
Dirk Schadendorf
Dirk Schadendorf
Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen
ایمیل تأیید شده در uk-essen.de
عنوان
نقل شده توسط
نقل شده توسط
سال
Improved survival with ipilimumab in patients with metastatic melanoma
FS Hodi, SJ O'Day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ...
New England Journal of Medicine 363 (8), 711-723, 2010
178182010
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
93922011
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
84402015
Nivolumab in previously untreated melanoma without BRAF mutation
C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ...
New England journal of medicine 372 (4), 320-330, 2015
63732015
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
50122018
Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells
FO Nestle, S Alijagic, M Gilliet, Y Sun, S Grabbe, R Dummer, G Burg, ...
Nature medicine 4 (3), 328-332, 1998
38851998
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
38712017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England journal of medicine 381 (16), 1535-1546, 2019
35762019
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
31982016
A landscape of driver mutations in melanoma
E Hodis, IR Watson, GV Kryukov, ST Arold, M Imielinski, JP Theurillat, ...
Cell 150 (2), 251-263, 2012
30832012
Improved overall survival in melanoma with combined dabrafenib and trametinib
C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ...
New England Journal of Medicine 372 (1), 30-39, 2015
30702015
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
30682018
Genomic classification of cutaneous melanoma
R Akbani, KC Akdemir, B áArman Aksoy, M Albert, A Ally, SB Amin, ...
Cell 161 (7), 1681-1696, 2015
29152015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ...
Science 350 (6257), 207-211, 2015
29142015
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
28302018
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
26742012
Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
D Schadendorf, FS Hodi, C Robert, JS Weber, K Margolin, O Hamid, ...
Journal of clinical oncology 33 (17), 1889-1894, 2015
25242015
Pan-cancer analysis of whole genomes
Nature 578 (7793), 82-93, 2020
2513*2020
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
24262018
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
22722018
سیستم در حال حاضر قادر به انجام عملکرد نیست. بعداً دوباره امتحان کنید.
مقاله‌ها 1–20